Clinical outcome following lung transplantation in patients with cystic fibrosis colonised with Burkholderia cepacia complex: Results from two French centres

Thorax

Volumn 63, Issue 8, 2008, Pages 732-737

  Boussaud, V ^a   Guillemain, R ^a   Grenet, D ^b   Coley, N ^c   Souilamas, R ^a   Bonnette, P ^b   Stern, M ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b FOCH HOSPITAL   (France)

^c CHU PURPAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL INFECTION; BRONCHIOLITIS OBLITERANS; BURKHOLDERIA; BURKHOLDERIA CEPACIA COMPLEX; BURKHOLDERIA MULTIVORANS; BURKHOLDERIA STABILIS; BURKHOLDERIA VIETNAMIENSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; EXTUBATION; FEMALE; GRAFT FAILURE; GRAFT RECIPIENT; HUMAN; INCIDENCE; LUNG TRANSPLANTATION; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPTICEMIA; SURGICAL MORTALITY; UNIVARIATE ANALYSIS;

EID: 49149124132     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.2007.089458     Document Type: Article

References (37)

1. Trulock EP, Edwards LB, Taylor DO, et al. Registry of the International Society for Heart and Lung Transplantation: twenty-third official adult lung and heart-lung transplantation report - 2006. J Heart Lung Transplant 2006;25:880-92.
2. Liou TG, Adler FR, Huang D. Use of lung transplantation survival models to refine patient selection in cystic fibrosis. Am J Respir Crit Care Med 2005;171:1053-9.
3. Govan JR, Deretic V. Microbial pathogenesis in cystic fibrosis: mucoid Pseudomonas aeruginosa and Burkholderia cepacia. Microbiol Rev 1996;60:539-74.
4. Muhdi K, Edenborough FP, Gumery L, et al. Outcome for patients colonised with Burkholderia cepacia in a Birmingham adult cystic fibrosis clinic and the end of an epidemic. Thorax 1996;51:374-7.
5. Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143:1007-17.
6. Whiteford ML, Wilkinson JD, McColl JH, et al. Outcome of Burkholderia (Pseudomonas) cepacia colonisation in children with cystic fibrosis following a hospital outbreak. Thorax 1995;50:1194-8.
7. Frangolias DD, Mahenthiralingam E, Rae S, et al. Burkholderia cepacia in cystic fibrosis. Variable disease course. Am J Respir Crit Care Med 1999;160(5 Pt 1):1572-7.
8. Ledson MJ, Gallagher MJ, Jackson M, et al. Outcome of Burkholderia cepacia colonisation in an adult cystic fibrosis centre. Thorax 2002;57:142-5.
9. Fitzgerald DA, Cooper DM, Paul M, et al. Burkholderia cepacia in cystic fibrosis: novel Australian cluster strain without accelerated respiratory deterioration. J Paediatr Child Health 2001;37:130-6.
10. Snell GI, de Hoyos A, Krajden M, et al. Pseudomonas cepacia in lung transplant recipients with cystic fibrosis. Chest 1993;103:466-71.
11. Egan JJ, McNeil K, Bookless B, et al. Post-transplantation survival of cystic fibrosis patients infected with Pseudomonas cepacia. Lancet 1994;344:552-3.
12. De Soyza A, McDowell A, Archer L, et al. Burkholderia cepacia complex genomovars and pulmonary transplantation outcomes in patients with cystic fibrosis. Lancet 2001;358:1780-1.
13. De Soyza A, Morris K, McDowell A, et al. Prevalence and clonality of Burkholderia cepacia complex genomovars in UK patients with cystic fibrosis referred for lung transplantation. Thorax 2004;59:526-8.
14. Chaparro C, Maurer J, Gutierrez C, et al. Infection with Burkholderia cepacia in cystic fibrosis: outcome following lung transplantation. Am J Respir Crit Care Med 2001;163:43-8.
15. Kalish LA, Waltz DA, Dovey M, et al. Impact of Burkholderia dolosa on lung function and survival in cystic fibrosis. Am J Respir Crit Care Med 2006;173:421-5.
16. Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-52.
17. Chabanon G, Segonds C, Clavel-Batut P, et al. Burkholderia et bactéries apparentées: rapport épidémiologique 2004. Toulouse: Observatoire Cepacia, Laboratoire de bactériologie- Hygiène, Institut fédératif de biologie, Hôpital Purpan-Toulouse, 2004.
18. Cystic Fibrosis Foundation. Patient Registry 2005 Annual Report. Bethesda: Cystic Fibrosis Foundation, 2006.
19. Mahenthiralingam E, Vandamme P, Campbell ME, et al. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis 2001;33:1469-75.
20. Speert DP, Henry D, Vandamme P, et al. Epidemiology of Burkholderia cepacia complex in patients with cystic fibrosis, Canada. Emerg Infect Dis 2002;8:181-7.
21. LiPuma JJ, Spilker T, Gill LH, et al. Disproportionate distribution of Burkholderia cepacia complex species and transmissibility markers in cystic fibrosis. Am J Respir Crit Care Med 2001;164:92-6.
22. Jones AM, Dodd ME, Govan JR, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004;59:948-51.
23. Segonds C, Heulin T, Marty N, et al. Differentiation of Burkholderia species by PCR-restriction fragment length polymorphism analysis of the 16S rRNA gene and application to cystic fibrosis isolates. J Clin Microbiol 1999;37:2201-8.
24. Sun L, Jiang RZ, Steinbach S, et al. The emergence of a highly transmissible lineage of cbl+ Pseudomonas (Burkholderia) cepacia causing CF centre epidemics in North America and Britain. Nat Med 1995;1:661-6.
25. Palfreyman RW, Watson ML, Eden C, et al. Induction of biologically active interleukin-8 from lung epithelial cells by Burkholderia (Pseudomonas) cepacia products. Infect Immun 1997;65:617-22.
26. De Soyza A, Ellis CD, Khan CM, et al. Burkholderia cenocepacia lipopolysaccharide, lipid A, and proinflammatory activity. Am J Respir Crit Care Med 2004;170:70-7.
27. Hutchison ML, Poxton IR, Govan JR. Burkholderia cepacia produces a hemolysin that is capable of inducing apoptosis and degranulation of mammalian phagocytes. Infect Immun 1998;66:2033-9.
28. Kooi C, Cox A, Darling P, et al. Neutralizing monoclonal antibodies to an extracellular Pseudomonas cepacia protease. Infect Immun 1994;62:2811-17.
29. McKenney D, Allison DG. Effects of growth rate and nutrient limitation on virulence factor production in Burkholderia cepacia. J Bacteriol 1995;177:4140-3.
30. Lamothe J, Huynh KK, Grinstein S, et al. Intracellular survival of Burkholderia cenocepacia in macrophages is associated with a delay in the maturation of bacteria-containing vacuoles. Cell Microbiol 2007;9:40-53.
31. Greenberg EP. Bacterial communication: tiny teamwork. Nature 2003;424:134.
32. Aris RM, Routh JC, LiPuma JJ, et al. Lung transplantation for cystic fibrosis patients with Burkholderia cepacia complex. Survival linked to genomovar type. Am J Respir Crit Care Med 2001;164:2102-6.
33. Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161:1206-12.
34. Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005;366:463-71.
35. Munford RS, Varley AW. Shield as signal: lipopolysaccharides and the evolution of immunity to gram-negative bacteria. PLoS Pathog 2006;2:e67.
36. Hosenpud JD, Bennett LE, Keck BM, et al. Effect of diagnosis on survival benefit of lung transplantation for end-stage lung disease. Lancet 1998;351:24-7.
37. Camby C. Rapport annuel 2005 - Bilan de activités de l'agence de la biomédecine. Agence de la Biomédecine, 2005:111-15.